Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/9867
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Piessevaux, H. | - |
dc.contributor.author | BUYSE, Marc | - |
dc.contributor.author | De Roock, W. | - |
dc.contributor.author | Prenen, H. | - |
dc.contributor.author | Schlichting, M. | - |
dc.contributor.author | Van Cutsem, E. | - |
dc.contributor.author | Tejpar, S. | - |
dc.date.accessioned | 2009-10-07T07:36:55Z | - |
dc.date.available | 2009-10-07T07:36:55Z | - |
dc.date.issued | 2009 | - |
dc.identifier.citation | ANNALS OF ONCOLOGY, 20(8). p. 1375-1382 | - |
dc.identifier.issn | 0923-7534 | - |
dc.identifier.uri | http://hdl.handle.net/1942/9867 | - |
dc.description.abstract | Patients and methods: Of the 329 patients, 289 had a measurement both at baseline and week 6. Tumor shrinkage was expressed as a relative decrease compared with baseline and categorized according to a previously reported cut-off value (similar to 10%) or used as a continuous variable. Results: Median time to progression (TTP) was 6.1 [95% confidence interval (CI) 5.1-7.2] versus 1.5 months (95% CI 1.4-1.7) in patients with [99 patients (34.3%)] or without [190 patients (65.7%)] tumor shrinkage, respectively, at week 6 [hazard ratio (HR) 0.23 (95% CI 0.17-0.32)]. The median overall survival (OS) was 13.7 (CI NA) versus 6.9 months (95% CI 6.1-7.7) [HR 0.21 (95% CI 0.14-0.32)], respectively. In a multivariate model, early tumor decrease outperformed skin toxicity as a predictor of long-term outcome. Conclusions: Tumor shrinkage at 6 weeks is a strong predictor of TTP and OS in cmCRC patients treated with cetuximab with or without irinotecan. This suggests early tumor shrinkage is the hallmark of efficacy of cetuximab and reliably identifies the subpopulation that is sensitive to the drug. Early tumor shrinkage can be used as a marker of efficacy in clinical practice, as such or in combination. | - |
dc.language.iso | en | - |
dc.publisher | OXFORD UNIV PRESS | - |
dc.subject.other | cetuximab; metastatic colorectal cancer; tumor measurements | - |
dc.title | Radiological tumor size decrease at week 6 is a potent predictor of outcome in chemorefractory metastatic colorectal cancer treated with cetuximab (BOND trial) | - |
dc.type | Journal Contribution | - |
local.bibliographicCitation.conferencename | 44th Annual Meeting of the American-Society-of-Clinical-Oncology | - |
local.bibliographicCitation.conferenceplace | Chicago, IL, MAY 30-JUN 03, 2008 | - |
dc.identifier.epage | 1382 | - |
dc.identifier.issue | 8 | - |
dc.identifier.spage | 1375 | - |
dc.identifier.volume | 20 | - |
local.format.pages | 8 | - |
local.bibliographicCitation.jcat | A1 | - |
dc.description.notes | [De Roock, W.; Prenen, H.; Van Cutsem, E.; Tejpar, S.] Univ Hosp Gasthuisberg, Digest Oncol Unit, B-3000 Louvain, Belgium. [Piessevaux, H.] Univ Catholique Louvain, Serv Gastroenterol, Clin Univ St Luc, B-1200 Brussels, Belgium. [Buyse, M.] Int Inst Drug Dev, Louvain, Belgium. [Buyse, M.] Univ Hasselt, Ctr Stat, Diepenbeek, Belgium. [Schlichting, M.] Merck KGaA, Darmstadt, Germany. | - |
local.type.refereed | Refereed | - |
local.type.specified | Article | - |
dc.bibliographicCitation.oldjcat | A1 | - |
dc.identifier.doi | 10.1093/annonc/mdp011 | - |
dc.identifier.isi | 000268806700011 | - |
item.fullcitation | Piessevaux, H.; BUYSE, Marc; De Roock, W.; Prenen, H.; Schlichting, M.; Van Cutsem, E. & Tejpar, S. (2009) Radiological tumor size decrease at week 6 is a potent predictor of outcome in chemorefractory metastatic colorectal cancer treated with cetuximab (BOND trial). In: ANNALS OF ONCOLOGY, 20(8). p. 1375-1382. | - |
item.fulltext | No Fulltext | - |
item.contributor | Piessevaux, H. | - |
item.contributor | BUYSE, Marc | - |
item.contributor | De Roock, W. | - |
item.contributor | Prenen, H. | - |
item.contributor | Schlichting, M. | - |
item.contributor | Van Cutsem, E. | - |
item.contributor | Tejpar, S. | - |
item.validation | ecoom 2010 | - |
item.accessRights | Closed Access | - |
crisitem.journal.issn | 0923-7534 | - |
crisitem.journal.eissn | 1569-8041 | - |
Appears in Collections: | Research publications |
SCOPUSTM
Citations
57
checked on Sep 3, 2020
WEB OF SCIENCETM
Citations
66
checked on Oct 4, 2024
Page view(s)
90
checked on May 23, 2023
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.